Introduction of lipidization - cationization motifs affords systemically bioavailable neuropeptide Y and neurotensin analogs with anticonvulsant activities

Journal of Peptide Science

Volumn 16, Issue 9, 2010, Pages 486-495

  Green, Brad R ^a   White, Karen L ^a   McDougle, Daniel R ^a   Zhang, Liuyin ^a   Klein, Brian ^b   Scholl, Erika A ^a   Pruess, Timothy H ^a   White, H Steve ^a   Bulaj, Grzegorz ^a  

^a UNIVERSITY OF UTAH   (United States)

^b NeuroAdjuvants Inc   (United States)

Author keywords

Bioavailability; Blood brain barrier; Chemical modifications; Epilepsy; Neurotensin; NPY

Indexed keywords

NEUROPEPTIDE Y DERIVATIVE; NEUROTENSIN DERIVATIVE; NPY BBB 2; NT BBB 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BIOAVAILABILITY; BLOOD BRAIN BARRIER; CIRCULAR DICHROISM; DISEASE MODEL; DOSE RESPONSE; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EPILEPSY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF;

ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; CATIONS; EPILEPSY; LIPIDS; NEUROPEPTIDE Y; NEUROTENSIN; RATS; RECEPTORS, NEUROPEPTIDE Y; RECEPTORS, NEUROTENSIN;

ANIMALIA;

EID: 77957293457     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1266     Document Type: Article

References (50)

1. 5 receptors. Eur. J. Neurosci. 2005; 22: 1417-1430.
2. Lee H-K, Zhang L, Smith MD, White HS, Bulaj G. Glycosylated neurotensin analogues exhibit sub-picomolar anticonvulsant potency in a pharmacoresistant model of epilepsy. Chem. Med. Chem. 2009; 4: 400-405.
3. Mazarati AM. Galanin and galanin receptors in epilepsy. Neuropeptides 2004; 38: 331-343.
4. Brasnjevic I, Steinbusch HWM, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood - brain barrier. Prog. Neurobiol. 2009; 87: 212-251.
5. van de Waterbeemd H, Lennernas H, Artursson P. Drug Bioavailability: Estimation of Solubility, Permeability, Adsorption and Bioavailability. Wiley-VCH: Weinheim, 2003.
6. Egleton RD, Davis TP. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997; 18: 1431-1439. (Pubitemid 27519756)
7. Cabrele C, Beck-Sickinger AG. Molecular characterization of the ligand - receptor interaction of the neuropeptide Y family. J. Pept. Sci. 2000; 6: 97-122.
8. Parker SL, Balasubramaniam A, Neuropeptide Y. Y2 receptor in health and disease. Br. J. Pharmacol. 2008; 153: 420-431.
9. Foti S, Haberman RP, Samulski RJ, McCown TJ. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses activity in vivo. Gene Ther. 2007; 14: 1534-1536.
10. Noe F, Frasca A, Balducci C, Carli M, Sperk G, Ferraguti F, Pitkanen A, Bland R, Fitzsimons H, During M, Vezzani A. Neuropeptide Y. overexpression using recombinant adeno-associated viral vectors. Neurotherapeutics 2009; 6: 300-306.
11. Beck-Sickinger AG, Wieland HA, Wittneben H, Willim K-D, Rudolf K, Jung G. Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors with distinguished conformations. Eur. J. Biochem. 1994; 225: 947-957.
12. Beck-Sickinger AG, Jung G. Structure - activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors. Biopolymers 1995; 37: 123-142.
13. Krstenansky JL, Owen TJ, Buck SH, Hagaman KA, McLean LR. Centrally truncated and stabilized porcine neuropeptide Y analogs: design, synthesis, and mouse brain receptor binding. Proc. Natl. Acad. Sci. 1989; 86: 4377-4381.
14. Rist B, Wieland HA, Willim K-D, Beck-Sickinger AG. A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor. J. Pept. Sci. 1995; 1: 341-348.
15. Rist B, Zerbe O, Ingenhoven N, Scapozza L, Peers C, Vaughan PFT, McDonald RL, Weiland HA, Beck-Sickinger AG. Modified, cyclic dodecapeptide analog of neuropeptide Y is the smallest full agonist at the human Y2 receptor. FEBS 1996; 394: 169-173.
16. Cox HM, Krstenansky JL. The effects of selective amino acid substitution upon neuropeptide Y antisecretory potency in rat jejunum mucosa. Peptides 1991; 12: 323-327.
17. Cáceda R, Kinkead B, Nemeroff CB. Neurotensin: role in psychiatric and neurologic diseases. Peptides 2006; 27: 2385-2404. (Pubitemid 44402784)
18. Boules M, Fredrickson P, Richelson E. Bioactive analogs of neurotensin: focus on CNS effects. Peptides 2006; 27: 2523-2533.
19. Dobner PR. Neurotensin and pain modulation. Peptides 2006; 27: 2405-2414.
20. Fürst S. Transmitters involved in antinociception in the spinal chord. Brain Res. Bull. 1999; 48: 129-141.
21. Henry JA, Horwell DC, Meecham KG, Rees DC. A structure - affinity study of the amino acid side-chains of neurotensin: N and C terminal deletions and Ala-scan. Bioorg. Med. Chem. Lett. 1993; 3: 949-952.
22. Tyler-McMahon BM, Boules M, Richelson E. Neurotensin: peptide for the nextmillenium. Regul. Pept. 2000; 93: 125-136.
23. Bredeloux P, Cavelier F, Dubuc I, Vivet B, Costentin J, Martinez J. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Pro- Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood - brain barrier. J. Med. Chem. 2008; 51: 1610-1616.
24. Kokko KP, Hadden MK, Orwig KS, Mazella J, Dix TA. In vitro analysis of stable, receptor-selective neurotensin [8-13] analogs. J. Med. Chem. 2003; 46: 4141-4148.
25. Zhang L, Lee H-K, Pruess TH, White HS, Bulaj G. Synthesis and applications of polyamine amino acid residues: improving the bioactivity of an analgesic neuropeptide, neurotensin. J. Med. Chem. 2009; 52: 1514-1517.
26. Bulaj G, Green BR, Lee H-K, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J. Med. Chem. 2008; 51: 8038-8047.
27. Zhang L, Robertson CR, Green BR, Pruess TH, White HS, Bulaj G. Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J.Med. Chem. 2009; 52: 1310-1316.
28. White HS, Scholl EA, Klein BD, Flynn SP, Pruess TH, Green BR, Zhang L, Bulaj G. Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models. Neurotherapeutics 2009; 6: 372-380.
29. Egleton RD, Davis TP. Development of neuropeptide drugs that cross the blood - brain barrier. NeuroRx 2005; 2: 44-53.
30. Fuchs SM, Raines RT. Internalization of cationic peptides: the road less (ormore?) traveled. Cell.Mol. Life Sci. 2006; 63: 1819-1822.
31. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 2003; 278: 31192-31201.
32. Wang J, Wu D, Shen WC. Structure - activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm. Res. 2002; 19: 609-614.
33. Chen Y-H, Yang JT, Chau KH. Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry 1974; 13: 3350-3359.
34. Wu C-SC, Ikeda K, Yang JT. Ordered conformation of polypeptides and proteins in acidic dodecylsulfate solution. Biochemistry 1981; 20: 566-570.
35. Cheng Y-C, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973; 22: 3099-3108.
36. Langer M, Bella RL, Garcia-Garayoa E, Beck-Sickinger AG. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug. Chem. 2001; 12: 1028-1034.
37. Craig AG, Norberg T, Griffin D, Hoeger C, Akhtar M, Schmidt K, Low W, Dykert J, Richelson E, Navarro V, Mazella J, Watkins M, Hillyard D, Imperial J, Cruz LJ, Olivera BM. Contulakin-G, an O-glycosylated invertebrate neurotensin. J. Biol. Chem. 1999; 274: 13752-13759.
38. Malakoutikhah M, Teixidó M, Giralt E. Toward and optimal blood - brain barrier shuttle by synthesis and evaluation of peptide libraries. J. Med. Chem. 2008; 51: 4881-4889.
39. Svenson J, Brandsdal B, Stensen W, Svendsen JS. Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J. Med. Chem. 2007; 50: 3334-3339.
40. Manezo Y, Khatchadourian C. Peptides bound to albumin. Life Sci. 1986; 39: 1751-1753.
41. Robertson CR, Scholl EA, Pruess TH, Green BR, White HS, Bulaj G. Engineering galanin analogues that discriminate between GalR1 and GalR2 subtypes and exhibit anticonvulsant activity following systemic delivery. J. Med. Chem. 2010; 53: 1871-1875.
42. Tyler-McMahon BM, Stewart JA, Farinas F, McCormick DJ, Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur. J. Pharmacol. 2000; 390: 107-111.
43. Hadden MK, Orwig KS, Kokko KP, Mazella J, Dix TA. Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues. Neuropharmacology 2005; 49: 1149-1159.
44. MacNeil DS. NPY Y1 and Y5 receptor selective antagonists as antiobesity drugs. Curr. Top. Med. Chem. 2007; 7: 1721-1733.
45. Gicquel S, Mazarguil H, Desprat C, Allard M, Devillers J-P, Simonet G, Zajac J-M. Structure - activity study of neuropeptide FF: contribution of N-terminal regions to affinity and activity. J.Med. Chem. 1994; 37: 3477-3481.
46. Mantey SA, Gonzalez N, Schumann M, Pradhan TK, Shen L, Coy DH, Jensen RT. Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands. J. Pharmacol. Exp. Ther. 2006; 319: 980-989.
47. Guerrini R, Caló G, Lambert DG, Carrá G, Arduin M, Barnes TA, McDonald J, Rizzi D, Trapella C, Marzola E, Rowbotham DJ, Regoli D, Salvadori S. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands. J. Med. Chem. 2005; 48: 1421-1427.
48. Matsumoto M, Hosada H, Kitajima Y, Morozumi N, Minamitake Y, Tanaka S, Matsuo H, Kojima M, Hayashi Y, Kanagawa K. Structure - activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem. Biophys. Res. Commun. 2001; 287: 142-146.
49. Reinscheid RK, Ardati A, Frederick J, Monsma J, Civelli O. Structure - activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. 1996; 271: 14163-14168.
50. Hruby VJ. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov. 2002; 1: 847-858.